LAVIPHARM S.A. NA EO 1 (BXA0) - Total Liabilities
Based on the latest financial reports, LAVIPHARM S.A. NA EO 1 (BXA0) has total liabilities worth €72.52 Million EUR (≈ $84.78 Million USD) as of December 2024. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore LAVIPHARM S.A. NA EO 1 (BXA0) net asset momentum to track the company's year-over-year net asset growth rate.
LAVIPHARM S.A. NA EO 1 - Total Liabilities Trend (2021–2024)
This chart illustrates how LAVIPHARM S.A. NA EO 1's total liabilities have evolved over time, based on quarterly financial data. See how much free cash does LAVIPHARM S.A. NA EO 1 generate to measure how efficiently the company converts operating cash flow to free cash.
LAVIPHARM S.A. NA EO 1 Competitors by Total Liabilities
The table below lists competitors of LAVIPHARM S.A. NA EO 1 ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Aekyung Petrochemical Co Ltd
KO:161000
|
Korea | ₩677.90 Billion |
|
Pengana Private Equity Trust
AU:PE1
|
Australia | AU$15.18 Million |
|
Veranda Learning Solutions Limited
NSE:VERANDA
|
India | Rs8.74 Billion |
|
Linzhou Heavy Machinery Group Co Ltd
SHE:002535
|
China | CN¥3.16 Billion |
|
Eastern Water Resources Development and Management Public Company Limited
BK:EASTW
|
Thailand | ฿16.37 Billion |
|
Habco Trans Maritima
JK:HATM
|
Indonesia | Rp272.19 Billion |
|
Forafric Global PLC Ordinary Shares
NASDAQ:AFRI
|
USA | $240.76 Million |
|
Eveready Industries India Limited
NSE:EVEREADY
|
India | Rs5.91 Billion |
Liability Composition Analysis (2021–2024)
This chart breaks down LAVIPHARM S.A. NA EO 1's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see LAVIPHARM S.A. NA EO 1 market cap and net worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.15 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.37 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.58 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how LAVIPHARM S.A. NA EO 1's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for LAVIPHARM S.A. NA EO 1 (2021–2024)
The table below shows the annual total liabilities of LAVIPHARM S.A. NA EO 1 from 2021 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | €72.52 Million ≈ $84.78 Million |
+0.70% |
| 2023-12-31 | €72.02 Million ≈ $84.19 Million |
-2.49% |
| 2022-12-31 | €73.86 Million ≈ $86.34 Million |
+17.83% |
| 2021-12-31 | €62.68 Million ≈ $73.28 Million |
-- |
About LAVIPHARM S.A. NA EO 1
Lavipharm S.A. engages in the research, development, manufacture, import, marketing, sale, and wholesale of pharmaceutical, cosmetics, and healthcare products to physicians and pharmacists in Greece and internationally. The company offers pharmaceutical products for cardiology, oncology-urology, central nervous system, chronic pain, and self- treatment. It also provides prescription medicines and… Read more